CombiMatrix Corporation
CBMX
NASDAQ6.25
USD
-0.30
- -
CIK
0001383183
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.49
5Y
- -
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Dec 16, 2002
- CIK
- 0001383183
- Similar Companies
- Business
- CombiMatrix Corporation (NASDAQ: CBMX) provides specialized clinical diagnostic laboratory services focused on prenatal genetics, developmental disorders, and miscarriage analysis. The company offers genetic testing services including chromosomal microarray analysis (CMA) for constitutional and oncology applications; noninvasive prenatal testing (NIPT); carrier screening for hereditary conditions; and molecular diagnostics for recurrent pregnancy loss and pediatric developmental delays. These services are delivered through its CLIA-certified laboratories serving obstetricians, maternal-fetal medicine specialists, pediatric neurologists, and genetic counselors across the United States. Founded in 2006 and headquartered in Irvine, California, CombiMatrix operates primarily in the molecular diagnostics segment of the healthcare industry, targeting reproductive health and pediatric genetics markets with a focus on high-complexity testing. In recent developments, the company was acquired by NeuroPointDx in 2018, marking a significant strategic shift toward integration with advanced neurological diagnostics capabilities; this transaction enhanced its portfolio without a ticker change. No major funding rounds, new product launches, or reorganizations have been reported in the last 1-2 years, maintaining stable operations under its established brand.